Compare Abbott Laboratories (ABT) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Robinhood Markets, Inc. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Robinhood Markets, Inc. trades at $112.91 (market cap $101.67B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| ABT | HOOD | |
|---|---|---|
Market Cap | $166.94B | $101.67B |
Sector | Health | Technology |
52-Week High | $136.62 | $152.46 |
52-Week Low | $82.57 | $65.16 |
Enterprise Value | $193.69B | $102.87B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Robinhood (HOOD) trades at $112.90, up 0.15% with strong technical momentum as it approaches resistance near $116. The stock shows robust fundamentals with 2025 revenue reaching $4.47 billion and net income of $1.88 billion, though valuation metrics remain elevated with a P/E of 57.06. Recent positive sentiment stems from international expansion and new product launches, including AI-powered trading tools and the Trump Accounts program announced July 2026.
Outlook remains positive with 73% analyst buy ratings and $108.13 consensus target, though the stock trades above target. Key opportunities include continued revenue growth and banking expansion, while risks involve high valuation multiples and cryptocurrency revenue volatility. Q2 2026 earnings on July 29 will be crucial for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
